ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: House Fills Subcommittee Positions; Senate Schedules NCI Appropriations Hearing Feb. 18

February 13, 1981

Isis 3521 Gets Fast-track Status For FDA Review.

December 1, 2000

Women’s Health Initiative Trial Produced $37.1 Billion in Returns

May 9, 2014

ASCO Honors Community Practices For Trial Participation.

June 1, 2007

President Accepts Compromise On HEW Money Bill; Cancer Gets $523.6 Million

December 21, 1973

Crout Resigns As Director Of FDA Drugs Bureau

July 11, 1980